Selling a psychiatry practice requires a buyer process that accounts for provider scarcity, prescribing continuity, payer mix, patient retention, medical leadership, and how much of the business depends on the selling psychiatrist or owner. Buyers will evaluate revenue, but they will also test whether clinical capacity and patient care can continue after closing. The strongest process explains the practice clearly, protects confidentiality, qualifies buyers, and prepares for diligence around providers, documentation, credentialing considerations, and transition risk.
For the broader process, see how to sell your behavioral health business. Before outreach begins, a behavioral health practice valuation can clarify how buyers may view earnings, risk, and transferability.
Psychiatry practices typically sell for 3x to 6x adjusted EBITDA. Multi-prescriber group practices with nurse practitioner or physician assistant extenders, strong payer mix, and scalable infrastructure command the upper end. Solo psychiatrist practices may be valued on revenue or collections due to key-person concentration and patient panel transferability limits.
| Practice Profile | Revenue Range | Multiple Range | Key Driver |
|---|---|---|---|
| Solo psychiatrist, no extenders | $300K-$900K | 2.5x-4x EBITDA or 0.5x-0.8x revenue | Key-person risk, patient panel transferability |
| Small group, 2-3 prescribers | $700K-$2.5M | 3.5x-5x EBITDA | Provider depth, panel diversity |
| Multi-prescriber group + NPs/PAs | $1.5M-$5M | 4x-6x EBITDA | Supervision depth, scalable capacity |
| Telepsychiatry-integrated | $1M+ | 4.5x-6x EBITDA | Geographic reach, platform asset |
| High private-pay / self-pay mix | Any | +0.5x-1x premium | Margin profile, no payer transfer risk |
| Medicaid-heavy | Any | Discount to above | Reimbursement compression, audit exposure |
These ranges are illustrative. Actual multiples vary by prescriber count, payer mix, state CPOM structure, documentation quality, buyer fit, and market conditions.
Premium multiples come from multiple prescribers with independent patient panels, NP and PA extenders under documented supervision, high private-pay or commercial payer concentration, telepsychiatry infrastructure with documented state licensure compliance, low founder billing concentration, organized PC/MSO structure, and clean DEA and licensure history.
Valuation risk increases when the founding psychiatrist holds most patient relationships, when there are no extenders or clinical depth, when DEA continuity is not planned, when payer mix is heavily Medicaid, when PC/MSO structure is absent in a CPOM state, or when patient records and billing are disorganized.
Psychiatry value is driven by whether the prescribers, patient panels, clinical autonomy, payer economics, and legal structure can survive an ownership transition.
The psychiatrist is the revenue-generating asset. In a solo practice, that creates key-person concentration. In a group with multiple prescribers, NPs, and PAs, the practice becomes a scalable platform. Buyers review prescriber-to-patient ratios, panel distribution, supervision agreements, and retention risk.
Psychiatric patient relationships are clinically sensitive. Patients on complex medication regimens or controlled substances need continuity and trust. A documented transition plan with warm handoffs, patient communication timing, and co-prescriber support is a deal asset, not just a clinical courtesy.
In CPOM states, buyers often cannot directly own the clinical practice. Psychiatry M&A may require a Professional Corporation for clinical services and a Management Services Organization for billing, operations, facilities, and administration. A clean structure protects deal timing and buyer confidence.
Private-pay and commercial psychiatry practices often command stronger margins and cleaner transition economics. Medicaid-heavy practices are still saleable, but buyers model reimbursement compression and audit exposure. Net revenue per prescriber hour matters more than gross collections alone.
Durable telepsychiatry infrastructure expands patient capacity and buyer interest when it is documented correctly. Buyers care about HIPAA-compliant platforms, state licensure, EHR integration, remote prescribing compliance, and whether the model is operationally sound rather than informal.
DEA registrations are issued to individual practitioners and do not transfer. For patients on controlled substances, prescribing continuity must be managed through a registered prescriber in the acquiring entity. This needs planning before outreach, not panic during diligence.
Psychiatry buyers must preserve clinical autonomy or risk losing the prescribers who create the value. Deal structure, governance, employment terms, and transition expectations should be addressed before signing an LOI.
The best buyer is not simply the highest bidder. In psychiatry, buyer fit determines whether prescribers stay and patient care continues.
Platforms acquire psychiatry practices to add medication management, prescriber capacity, and higher-acuity behavioral health services to existing therapy or outpatient networks.
Health systems buy psychiatry capacity to support broader networks, fill access gaps, and integrate psychiatric care into primary care, emergency, and outpatient settings.
Physician-led or clinician-owned buyers may be strong fits for practices where clinical autonomy, patient continuity, and local reputation matter more than a broad auction.
Telehealth and hybrid care buyers may value practices with durable telepsychiatry systems, documented multi-state licensure, and scalable prescriber workflows.
If you are a buyer seeking psychiatry practice acquisitions, see our buyer resources.
If you want to sell psychiatric practice assets, the advisor needs to understand the medical side of behavioral health M&A. Psychiatry m&a involves PC/MSO structure, CPOM, DEA continuity, controlled substances, patient transition, clinical autonomy, prescriber compensation, and payer economics. A general business broker will miss the issues that decide whether the deal closes.
Behavioral Health Business Broker can also help distinguish a psychiatry sale from a mental health practice sale or an outpatient behavioral health practice sale. Behavioral Health Business Broker works exclusively in behavioral health, and our process reflects how we work with behavioral health practice owners.
A prepared psychiatry practice sale often takes 4 to 8 months. PC/MSO structuring, DEA continuity, payer credentialing, and telehealth licensure can extend that timeline.
We assess adjusted EBITDA, prescriber count, payer mix, patient panel transferability, founder dependence, PC/MSO needs, telepsychiatry infrastructure, and clinical transition risk. The goal is a psychiatry practice valuation before buyer outreach begins.
Preparation includes prescriber rosters, compensation records, payer contracts, DEA and licensure documentation, patient panel data, telepsychiatry state coverage, EHR records, and any existing PC/MSO documents.
We contact buyers matched to your practice profile under NDA. Outreach is confidential and targeted to buyers that understand prescriber scarcity, clinical autonomy, and psychiatric patient transition.
Qualified buyers submit letters of intent covering price, structure, employment terms, governance, PC/MSO design, transition support, and any earnout obligations. We evaluate the full offer, not just the headline number.
Due diligence covers financials, payer contracts, prescriber retention, DEA and licensure status, controlled-substance continuity, patient panel transition, clinical records, telehealth compliance, PC/MSO structure, and employment agreements.
Psychiatry buyers scrutinize prescriber retention, patient continuity, credentialing considerations, payer mix, and whether medical leadership can transition.
Psychiatry practice sales need careful confidentiality because patient continuity and prescriber stability are central to value. Early buyer outreach should not expose the physician, staff, patient base, or payer relationships. Disclosure should be staged so serious buyers can evaluate fit without creating disruption before the transaction path is credible.
If you are considering a confidential sale, start with a private seller conversation. Behavioral Health Business Broker focuses on behavioral health M&A, not general small-business brokerage.
You can sell, but buyers will focus heavily on transition planning, patient continuity, prescriber retention, and whether revenue depends on your continued clinical role.
Buyers often value provider stability, patient demand, payer mix, documentation quality, scheduling capacity, medical leadership, and low dependence on one clinician.
Yes, provider scarcity can influence buyer interest, but only if clinical continuity and retention are credible. Scarcity does not remove diligence risk.
Request a valuation before outreach if you are considering a sale, planning succession, receiving buyer interest, or deciding whether to reduce your clinical role.
If you are considering a sale, start with a confidential conversation before exposing the business to buyers. Behavioral Health Business Broker can help you understand timing, valuation, buyer fit, confidentiality, and what diligence may require.
Not ready to sell yet? A valuation review can help clarify how buyers may view earnings, payer mix, provider stability, owner dependence, and transferability.
